Physician profile
Mitchell Wicker
NPI 1730182841
$1,787.58
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $225 · 2021: $339 · 2022: $215 · 2023: $234 · 2024: $115 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.19 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $402.11 | 2019-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $254.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.30 | 2020-2023 | Xifaxan |
| Abbvie INC. | $110.38 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $85.00 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $84.99 | 2019-2022 | |
| Novo Nordisk INC | $79.22 | 2019-2025 | Wegovy |
| Pfizer INC. | $78.33 | 2019-2020 | |
| Axsome Therapeutics, INC. | $68.47 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $64.60 | 2021-2023 | Glassia |
| Dexcom, INC. | $51.76 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $40.43 | 2022-2024 | Airsupra, Lokelma |
| Gilead Sciences, INC. | $31.65 | 2019-2025 | |
| Amgen INC. | $28.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $27.58 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Allergan, INC. | $17.49 | 2019 | |
| Neurelis, INC. | $17.14 | 2023 | Valtoco |
| Daiichi Sankyo INC. | $14.64 | 2022 | |
| Exact Sciences Corporation | $14.56 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $14.49 | 2023 | Jardiance |
| Abbott Laboratories | $13.19 | 2024 | Freestyle Libre 3 |
| Biogen, INC. | $11.89 | 2021 | |
| Si-Bone, INC. | $10.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Wicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.